The News London 365
  • Breaking News
  • Lifestyle
  • Coronavirus
  • Food
  • Politics
  • Sport
Sunday, June 26, 2022
London
+10°C
Privacy Policy
Copyright
Contact us
No Result
View All Result
  • Breaking News
  • Lifestyle
  • Coronavirus
  • Food
  • Politics
  • Sport
No Result
View All Result
The News London 365
No Result
View All Result
Home Coronavirus

WHO-led trial to study three anti-inflammatory drugs for COVID-19 patients By Reuters

The News London 365 by The News London 365
August 11, 2021
in Coronavirus
0
Royal Albert Hall back at capacity, but London landmark left in debt By Reuters

© Reuters. FILE PHOTO: A logo is pictured outside a building of the World Health Organization (WHO) during an executive board meeting on update on the coronavirus disease (COVID-19) outbreak, in Geneva, Switzerland, April 6, 2021. REUTERS/Denis Balibouse/File Photo

By Michael Shields and Dania Nadeem

ZURICH (Reuters) – The World Health Organization (WHO) said on Wednesday a clinical trial in 52 countries would study three anti-inflammatory drugs as potential treatments for COVID-19 patients.

“These therapies – artesunate, imatinib and infliximab – were selected by an independent expert panel for their potential in reducing the risk of death in hospitalised COVID-19 patients,” it said in a statement on the Solidarity PLUS trial.

The trial involves thousands of researchers at more than 600 hospitals, WHO Director General Tedros Adhanom Ghebreyesus told a news briefing from Geneva.

Finland is one of the first countries to enroll patients in the Solidarity PLUS trial, he added.

“There are many variants, and all variants can appear anywhere on the planet. And so having so many sites in so many different countries and regions will help us get to these answers as fast as possible,” said Marie Pierre Preziosi, co-lead of the research and development blueprint at the WHO.

Artesunate is already used for severe malaria, imatinib for certain cancers, and infliximab for diseases of the immune system such as Crohn’s Disease and rheumatoid arthritis.

The WHO warned countries to come together to combat the fast-spreading Delta variant of the coronavirus and urged equitable access to essential countermeasures.

“At the current trajectory, we could pass 300 million reported cases early next year. But we can change that. We’re all in this together, but the world is not acting like it,” Tedros said.

The WHO last week called for a halt on COVID-19 vaccine boosters until at least the end of September as the gap between vaccinations in wealthy and poor countries widens.

The original Solidarity trial last year found that all four treatments evaluated – remdesivir, hydroxychloroquine, lopinavir/ritonavir and interferon – had little or no effect in helping COVID patients. The WHO expects final results from this trial next month.

So far, only corticosteroids have been proven effective against severe and critical COVID-19.

The WHO said artesunate, produced by Ipca, is used to treat malaria. In the trial, it will be administered intravenously for seven days, using the standard dose recommended for the treatment of severe malaria.

Imatinib, produced by Novartis, is used to treat certain cancers. In the trial, it will be administered orally, once daily, for 14 days.

Infliximab, produced by Johnson and Johnson, is used to treat diseases of the immune system. In the trial, it will be administered intravenously as a single dose.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Previous Post

EU looking into new possible side-effects of mRNA COVID-19 shots By Reuters

Next Post

CDC recommends pregnant women get COVID-19 vaccine By Reuters

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

RECENT NEWS

Canada to send 8 armoured vehicles to Ukraine amid heavy weapons push

Canada to send 8 armoured vehicles to Ukraine amid heavy weapons push

June 26, 2022
My OCD makes me think I’m going to kill someone or be killed

My OCD makes me think I’m going to kill someone or be killed

June 26, 2022
Embracing quiet moments can change your life for the better – here’s how

Embracing quiet moments can change your life for the better – here’s how

June 26, 2022
The Big Happiness Interview: Sonia Choquette on why your intuition is your superpower

The Big Happiness Interview: Sonia Choquette on why your intuition is your superpower

June 26, 2022
I was told to wear a black bra to cure my breast cancer – these kinds of suggestions are dangerous

I was told to wear a black bra to cure my breast cancer – these kinds of suggestions are dangerous

June 26, 2022
£33m cash boost would ‘give us truly global appeal’

£33m cash boost would ‘give us truly global appeal’

June 26, 2022

Categories

Breaking News Coronavirus Daily Devotionals Food Health and Science Lifestyle Politics Sport What's On

Recent News

Canada to send 8 armoured vehicles to Ukraine amid heavy weapons push

Canada to send 8 armoured vehicles to Ukraine amid heavy weapons push

June 26, 2022
The News London 365

  • Privacy Policy
  • Copyright
  • Contact us
No Result
View All Result
  • Breaking News
  • Lifestyle
  • Coronavirus
  • Food
  • Politics
  • Sport

© 2022 JNews - Premium WordPress news & magazine theme by Jegtheme.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT